drugset / Trial / NCT03441581

Eluxadoline Bile Acid Malabsorption (BAM) Study

NCT03441581

Phase 4 Completed 24 enrolled Allergan
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the possibility of a differential effect of eluxadoline on altered bowel function in Irritable Bowel Syndrome with Diarrhea (IBS-D) participants with and without evidence of Bile Acid Malabsorption (BAM).

Timeline

Start
2018-02-23
Primary completion
2020-04-28
Completion
2020-04-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Eluxadoline Small molecule 100 mg Oral